Madrigal Pharmaceuticals Q3'26 Earnings Preview
Madrigal Pharmaceuticals is scheduled to report Q3'26 results before the market opens on November 3. EPS is estimated at (0.86) USD.
Related stories
Sentia Subsidiary HENT Wins NOK 208 Million Office Contract
HENT signed a NOK 208 million contract, excluding VAT, with SVG Property to build an approximately 5,000-square-meter office building in Stavanger. Construction is scheduled to sta
M impact | EQUITY | Nov 02, 2026, 03:30 PM UTC
Usio Schedules Q3 Fiscal 2026 Results Call and Company Update
Usio says it will hold a third-quarter fiscal 2026 results conference call and company update on November 10, 2026.
M impact | EQUITY | Nov 02, 2026, 03:30 PM UTC
Publix Reports Third-Quarter 2026 Results
Publix reported sales of $15 for the three months ended Sept. 26, 2026.
M impact | EQUITY | Nov 02, 2026, 03:30 PM UTC
Oracle raises funds from investors to expand AI business
Oracle raised funds from investors to fund expansion of its AI business, according to a regulatory filing submitted Monday, Reuters reports.
L impact | EQUITY | Nov 02, 2026, 03:30 PM UTC
Thai Union Posts Quarterly Net Profit of 1,346 Million Baht
M impact | EQUITY | Nov 02, 2026, 03:29 PM UTC
MIG Holdings Posts Q3 Loss as Property Income Falls
MIG Holdings entered the loss zone in the third quarter of 2026. Income from investment properties also declined during the quarter.
M impact | EQUITY | Nov 02, 2026, 03:29 PM UTC